EMA Authorised: Vevzuo (denosumab) — Biosimilar Collaborations Ireland Limited

View source ↗

Summary

The EMA authorised Vevzuo, a denosumab biosimilar, for bone neoplasms including Giant Cell Tumor of Bone.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bone Neoplasms
• Giant Cell Tumor of Bone

Drugs mentioned

• Vevzuo (denosumab)

Snippet

Status: Authorised. Therapeutic area: Neoplasms, Bone Tissue;Giant Cell Tumor of Bone. MAH: Biosimilar Collaborations Ireland Limited. Decision date: 27/03/2026